MetaVia Inc. MTVA
1.06 USD -0.04 (-3.21%)
As ofNov 20, 2026, 10:50 AM EST
1.04 Day range 1.10
0.966 52-week range 13.42
- YTD
- -87.47%
- 1 year
- -85.53%
Benzinga news
benzinga.com Metavia Announces Preclinical Data From Head-To-Head Study Comparing Novel GLP-1 DA-1726 With Retatrutide; Sees Statistically Significant Increase In Liver And Circulating FGF21 Expression; Plans Phase 2 Study In MetALD And ALD H2 2027 MetaVia Inc. (NASDAQ:MTVA), a clinical-stage biotechnology company focused on transforming liver-related cardiometabolic diseases, today announced positive preclinical data from a head-to-head study…
benzinga.com MetaVia Q3 EPS $(0.69) Beats $(0.73) Estimate MetaVia (NASDAQ:MTVA) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(0.73) by 5.48 percent. This is a 55.19 percent increase over losses of $(1.54) per…
benzinga.com MetaVia's Potential Drug Candidate Cuts Serum Uric Acid and Liver Fat MetaVia reports positive Phase 1 data showing that once-weekly DA-1726 significantly reduces serum uric acid and liver fat.benzinga.com MetaVia Announces Interim Data From Part 3B Of Its Phase 1 Clinical Trial Of DA-1726 Targeting Both GLP-1 And Glucagon Receptors; Results Demonstrate 68% Placebo-Adjusted Reduction In Liver Fat And 13.5% Placebo-Adjusted Body Weight Reduction Following 16 Weeks Of Once-Weekly DA-1726 Treatment In Otherwise Healthy Adults With Obesity; Plans Phase 2 For H2 2027 At Day 109, 10 of 12 DA-1726-treated participants (83%) in the MRI substudy achieved a relative liver fat reduction of at least 30%, compared with none on placebo. All DA-1726-treated participants…
benzinga.com MetaVia To Report Data From Its Phase 1 Clinical Study Of DA-1726 At Precision Liver Symposium 2026 MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Senti Biosciences (NASDAQ:SNTI) stock rose 51.8% to $0.27 during Monday's after-market session. The company's market cap stands at $5.9 million. Polyrizon (NASDAQ:PLRZ) shares increased by…
